In an Initial Decision announced on May 18, 2018, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in a complaint issued by the Federal Trade Commission against generic pharmaceutical company Impax Laboratories, Inc. The FTC’s January 2017 administrative complaint alleged that in June 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that […]